Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention, Clinical Effectiveness, Safety, Adherence, and Risk Compensation in all Populations
DOI:
https://doi.org/10.30994/sjik.v12i2.1021Keywords:
Human Immunodeficiency Virus (HIV), pre-exposure prophylaxis (PrEP), safetyAbstract
Based on WHO and UNAIDS reports in 2021, 38.4 million (33.9-43.8 million) HIV cases in the world, in Indonesia reported by 34 provinces, the number of people living with HIV found in the January-March 2022 period was 10,525 941,973 people have HIV, and 8,784 people are receiving ARV treatment. The aim of this study is to observe the literature on the clinical efficacy, safety, compliance and risk compliance of oral pre-exposure prophylaxis (PrEP) for HIV prevention in all population groups. A literature review was carried out by identifying national and international articles regarding pre-exposure prophylaxis (PrEP) for preventing HIV transmission. The database used was Google Scholar, Pubmed, Science Direct, The Lancet. There were 331 articles searched from the Pubmed online database, 14 articles, Proquest 134, Science Direct 105, The Lancet 2, Google Scholar 105. There were 20 articles that met the inclusion criteria and were processed.
References
Adams, J., Coquilla, R., Montayre, J., & Neville, S. (2019). Knowledge of HIV pre-exposure prophylaxis among immigrant Asian gay men living in New Zealand. Journal of Primary Health Care, 11(4), 351–358.https://doi.org/10.1071/HC19076.
Biello, K. B., Bazzi, A. R., Mimiaga, M. J., Biancarelli, D. L., Edeza, A., Salhaney, P., Childs, E., & Drainoni, M. L. (2018). Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs 16 Studies in Human Society 1608 Sociology. Harm Reduction Journal, 15(1), 1–13. https://doi.org/10.1186/s12954-018- 0263-5.
Brink ID, D. C. ten, Rowan Martin- Hughes1, Mark E. MinneryID 1, A. J. O., & Heather-Marie A. Schmidt2, 3, Shona Dalal3, Kimberly E. Green4, Reshmie Ramaurtarsing5, David P. Wilson1, 6, 7, S. L. K. (2022). Cost-effectiveness and impact of preexposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
B. X., Larsson, M., Rocha, L. E. C., Thorson, A., & Strömdahl, S. (2021). A qualitative assessment in acceptability and barriers to use pre- exposure prophylaxis (PrEP) among men who have sex with men: implications for service delivery in Vietnam.
Firmansyah, Doni, and Erawati. (2020). “Prevalensi Kejadian Infeksi HIV Pada Komunitas Homoseksual Dan Wanita Pekerja Seks Dengan Metode Imunokromatografi (Rapid Test) Di Kota Kediri.” Jurnal Sintesis 1 (1): 9–15.
Huang, X., Hou, J., Song, A., Liu, X., Yang, X., Xu, J., Zhang, J., Hu, Q., Chen, H., Chen, Y., Meyers, K., & Wu, H. (2018). Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: A systematic review and meta-analysis. Frontiers in Pharmacology, 9(SEP), 1–11.
Jourdain, H., de Gage, S. B., Desplas, D., & Dray-Spira, R. (2022). Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study.
M. (2021). Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland.
Maxwell, S., Shahmanesh, M., & Gafos, M. (2022). Pre-exposure prophylaxis (PrEP) uptake and adherence experiences of gay and bisexual men who engage in chemsex: A qualitative study. International Journal of Drug Policy, 103, 103630. https://doi.org/10.1016/j.drugpo.2022. 103630.
Murewanhema, G., Malisheni, M., & Takah, N. F. (2021). The effectiveness of tenofovir-based pre- exposure prophylaxis for prevention of hiv acquisition among sub- saharan african women at high risk: A systematic revieNguyen, L. H., Nguyen, H. L. T., Tran.
Najmah. (2016). Epidemiologi Penyakit Menular. Jakarta: Trans Info Media.
O Murchu et al., (2021). O Murchu, E., Teljeur, C., Hayes, C., Harrington, P., Moran, P., & Ryan,
O Murchu, E., Marshall, L., Teljeur, C., Harrington, P., Hayes, C., Moran, P., & Ryan, M. (2022). Oral pre- exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
Phillips, A. N., Bershteyn, A., Revill, P., Bansi-Matharu, L., Kripke, K., Boily, M. C., Martin- Hughes, R., Johnson, L. F., Mukandavire, Z., Jamieson, L., Meyer-Rath, G., Hallett,
Republik Indonesia. (2021). Pedoman Tatalaksana Program Percontohan Profilaksis Pra-Pajanan (PrEP) untuk Orang Berisiko Tinggi Terinveksi HIV di Indonesia.
T. R., Thomas, K. K., Nambi, F., Nakabugo, L., Kibuuka, J., Thomas, D., Feutz, E., Meisner, A., Ware, N. C., Wyatt, M.A., Simoni, J. M., Katz, I. T., Kadama,H., Baeten, J. M., Mujugira, A., Simoni, J., Donnell, D., Barnabas, R., … Pisarski, E. (2022). PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV- negative members of HIV- serodifferent couples: A stepped wedge cluster randomized trial.
UNAIDS. (2022). “Unaids 2022.” Unaids. 2022. https://www.unaids.org/en/resources/documents/2023/2022_unaids_data. Veronica. 2016. “Infeksi Human Immunodeficiency Virus Dan Acquired Immunodeficiency Syndrome,” 42. https://simdos.unud.ac.id/uploads/file_penelitian_1_dir/d5ff4e390bc5e7c52fb3d 21689f6f9e5.pdf.
